Special Issue

Animal Models of Human Pathology: Revision, Relevance and Refinements 2.0

Message from the Guest Editor

Use of animal models of human pathology is accepted on the assumption that it benefits humans. However, recent publications have shown that research on animals faces serious challenges. The increasing number of potential targets, molecular pathways or treatment strategies, which have been recognized as promising in animal models, have failed when translated into human trials. We have reached the point where the clinical relevance of animal models needs urgent clarification. The purpose of this Special issue is thus to promote submissions of high-quality papers of basic research using animal models to understand diseases and underlying mechanisms or to investigate new treatment strategies in various human diseases such as cancer, bowel diseases, kidney injury, Parkinson's disease, etc. New approaches towards the use of animal models or refinements of particular animal models of human pathology as well as methodological and welfare principles (such as experimental design and welfare or supportive measures in animal models) are also welcome.

Guest Editor

Dr. Martina Perše

Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Deadline for manuscript submissions

closed (31 March 2024)

MDPI

Biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).